High Tech Pharm

Founded in 1998 and listed on KOSDAQ in 2010, HiTechPharm is a specialist manufacturer of injectable antibiotic active pharmaceutical ingredients (APIs).

The company produces carbapenem-class antibiotic APIs, including sterile imipenem and ertapenem, at its headquarters and plant in Daeso-myeon, Eumseong County, and at its Chungju facility.

As of 2025, carbapenem-class products accounted for roughly 86-95% of total revenue, while cephalosporin-class sales were comparatively small at around KRW 1.8 billion. Sales are essentially all export-driven, with about 99.95% of revenue generated overseas and Europe alone accounting for more than 87%.

The largest shareholder is ACS Dobfar, a global Italian antibiotics company, and 2025 revenue derived from this single counterparty reached 87.4%, indicating heavy customer concentration.

The Chungju plant has secured both EU GMP and US FDA approvals for sterile imipenem, along with Italian AIFA approval and China/Taiwan DMF registrations, giving it entry barriers into regulated markets.

Domestically the company competes with firms such as Chong Kun Dang in carbapenem-related products built on original US-based MSD technology, while internationally it competes with players such as Taiwan's Savior.

In May 2026, a new CEO, Cha Hyun-jun, took the helm and set North American market expansion and diversification into new regions such as the Middle East, India and South America as priorities, while maintaining the existing Europe- and carbapenem-centered structure.

HiTechPharm's annual results have shown pronounced volatility.

Profitability that was weak in 2022, with revenue of KRW 102.9 billion and an operating margin of just 4.8%, improved through 2023 (revenue KRW 76.8 billion, margin 13.1%) and 2024 (revenue KRW 77.5 billion, margin 20.1%), before margins declined for a second straight year in 2025 to revenue of KRW 70.2 billion (down 9.5%), operating profit of KRW 12.9 billion (down 17.4%), and an 18.3% operating margin.

Net profit attributable to owners also fell from KRW 13.7 billion in 2024 to KRW 11.5 billion in 2025. On a quarterly basis, revenue declined from KRW 23.0 billion in Q2 2025 to KRW 17.9 billion in Q3 and KRW 14.0 billion in Q4, while operating profit held relatively steady at KRW 3.2-3.9 billion across those quarters.

However, Q1 2026 swung to a loss, with revenue of KRW 14.1 billion (down 7.4% year on year), an operating loss of KRW 1.1 billion, and a net loss of KRW 0.3 billion, which the company attributed to a temporary hit from equipment maintenance costs and stock compensation expenses.

Q2 2026 then rebounded sharply, with revenue surging to KRW 23.4 billion, operating profit of KRW 6.3 billion, and net profit attributable to owners of KRW 5.2 billion, marking a clear recovery from the prior quarter's weakness.

On the balance sheet, the debt ratio steadily fell from 32.3% in 2022 to 10.0% in 2025, and operating cash flow improved from negative KRW 3.7 billion in 2022 to KRW 14.7 billion in 2024 and KRW 17.0 billion in 2025, indicating strengthening cash generation.

Carbapenem-class antibiotics are broad-spectrum injectable drugs often described as a 'last resort' treatment for multidrug-resistant infections, and only a limited number of companies have the manufacturing capability, built on technology originally developed by US-based MSD.

HiTechPharm is one of the few domestic companies specializing in carbapenem API exports, maintaining competitiveness in a high-barrier market through multiple regulated-market approvals including US FDA, EU GMP, and Japan's PMDA.

Industry observers note that easing the company's Europe- and carbapenem-centric structure will be a key variable for future earnings stability.

In 2025, excessive price competition and dumping by Chinese producers, along with raw material supply instability following an explosion at an overseas intermediate material supplier, contributed to the earnings slowdown.

This illustrates that the broader API industry can be vulnerable to external shocks in supply chains and price competition.

Competitively, the company vies with domestic player Chong Kun Dang and overseas rival Savior of Taiwan in the carbapenem segment, and the new management team has framed its dedicated carbapenem production facilities and regulated-market certifications as a barrier that is difficult for competitors to replicate.

CEO Cha Hyun-jun, who took office in May 2026, has laid out expanded North American supply and diversification into new regions such as Asia, South America, the Middle East, and India as core growth strategies, while maintaining the existing Europe- and carbapenem-centered business.

The company has framed its US FDA approval not as mere registration but as proof of the global competitiveness of its dedicated carbapenem production facilities, emphasizing plans to expand supply chain relationships with North American finished-drug manufacturers.

To strengthen cost competitiveness, management said it is pursuing process improvements to raise yields, securing safety stock, diversifying suppliers, and strengthening in-house production capability for key intermediates.

The sharp rebound in revenue and profit in Q2 2026 following a temporary Q1 setback suggests one-off factors such as equipment maintenance are being resolved, but whether this momentum continues through the full year requires confirmation from subsequent quarterly results.

The company has described its Chungju and Daeso synthesis-building capital investments as a normal process to secure production stability and continuity, making it worth watching whether facility stabilization contributes to normalized production in the second half.

That said, the strategy to ease the carbapenem- and Europe-heavy structure and expand into North America and new markets remains directional, without specific numerical targets or confirmed timelines yet disclosed, so execution pace and results will need to be verified through further disclosures.